Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells 26,011 Shares of Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 26,011 shares of the business’s stock in a transaction on Wednesday, December 24th. The shares were sold at an average price of $35.68, for a total transaction of $928,072.48. Following the transaction, the chief accounting officer owned 15,000 shares in the company, valued at approximately $535,200. This represents a 63.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Louise Frederika Kooij also recently made the following trade(s):

• On Friday, December 26th, Louise Frederika Kooij sold 43,872 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $35.30, for a total value of $1,548,681.60.
• On Tuesday, December 23rd, Louise Frederika Kooij sold 75,117 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $36.21, for a total value of $2,719,986.57.

NewAmsterdam Pharma Trading Down 0.7%

NAMS stock traded down $0.25 during mid-day trading on Monday, hitting $35.02. The stock had a trading volume of 372,987 shares, compared to its average volume of 944,760. NewAmsterdam Pharma Company N.V. has a 1-year low of $14.06 and a 1-year high of $42.00. The company has a fifty day moving average of $37.08 and a 200 day moving average of $29.03. The stock has a market capitalization of $3.97 billion, a price-to-earnings ratio of -17.08 and a beta of 0.05.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.03). NewAmsterdam Pharma had a negative net margin of 627.59% and a negative return on equity of 28.30%. The firm had revenue of $0.35 million during the quarter, compared to the consensus estimate of $4.54 million. As a group, sell-side analysts expect that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.

Institutional Investors Weigh In On NewAmsterdam Pharma

Several hedge funds and other institutional investors have recently made changes to their positions in NAMS. PTM Wealth Management LLC acquired a new stake in shares of NewAmsterdam Pharma in the second quarter worth $256,000. Knights of Columbus Asset Advisors LLC acquired a new stake in NewAmsterdam Pharma in the 2nd quarter worth $595,000. Franklin Resources Inc. increased its holdings in shares of NewAmsterdam Pharma by 30.6% during the 2nd quarter. Franklin Resources Inc. now owns 334,212 shares of the company’s stock worth $6,053,000 after purchasing an additional 78,300 shares during the period. Frazier Life Sciences Management L.P. increased its holdings in shares of NewAmsterdam Pharma by 3.0% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 16,607,074 shares of the company’s stock worth $300,754,000 after purchasing an additional 490,656 shares during the period. Finally, Parkman Healthcare Partners LLC raised its position in shares of NewAmsterdam Pharma by 32.6% during the first quarter. Parkman Healthcare Partners LLC now owns 100,955 shares of the company’s stock valued at $2,067,000 after buying an additional 24,839 shares during the last quarter. 89.89% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the stock. Royal Bank Of Canada raised their price target on shares of NewAmsterdam Pharma from $39.00 to $44.00 and gave the company an “outperform” rating in a report on Thursday, November 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Wednesday, October 8th. The Goldman Sachs Group boosted their price target on NewAmsterdam Pharma from $30.00 to $37.00 and gave the stock a “neutral” rating in a research report on Tuesday, December 2nd. Needham & Company LLC upped their price target on NewAmsterdam Pharma from $40.00 to $46.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Finally, Stifel Nicolaus raised their price objective on NewAmsterdam Pharma from $44.00 to $50.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, NewAmsterdam Pharma has a consensus rating of “Moderate Buy” and a consensus price target of $45.90.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical?stage biopharmaceutical company focused on discovering and developing novel small?molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small?molecule candidates at various stages of preclinical and clinical evaluation.